<DOC>
	<DOC>NCT00261703</DOC>
	<brief_summary>Primary Objective: - Phase II: To determine the best treatment scheme (TPF vs. PF). - Phase III: To compare the time to progression and the treatment failure at the 3 arms. Secondary objectives: - To evaluate the safety at the 3 arms. - To compare the progression , overall survival and locoregional control at the 3 arms.</brief_summary>
	<brief_title>Docetaxel in Head and Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Head and Neck cancer locally advanced (oral cavity, oropharynx, hypopharynx or larynx) but without evident metastasis. Inoperable tumor after revision by a multidisciplinary oncology team. Proved epidermoid carcinoma. ECOG = 01 Good hematologic function (i.e, hemoglobin &gt; 10 g/dl, ...) Good hepatologic function Good renal function Pregnant or breastfeeding women. Potential childbearing women should use an effective conceptive method and should have a negative pregnancy test at least the week before entering the study. Nasopharynx, nasal cavity and paranasal sinusitis will be excluded Previous chemotherapeutic or radiotherapeutic treatment for this disease. Previous or current neoplasms in other locations, except in situ cervicouterine cancer properly treated or basal cell or squamous cell carcinoma Symptomatic peripheral neuropathy Other clinical severe diseases Concomitant treatment with corticoids within 6 months prior to inclusion. Concomitant treatment with any other neoplastic therapy Previous treatment for current disease. Loss of weight greater than 10% within the last 3 months. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>